<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Patient Stratification - Enhanced</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        body {
            font-family: Aptos, 'Segoe UI', sans-serif;
            background: white;
            padding: 40px 20px;
        }
        
        .slide {
            width: 960px;
            margin: 0 auto 60px;
            background: white;
            box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            border-radius: 8px;
            overflow: hidden;
        }
        
        .container {
            padding: 40px;
        }
        
        .title {
            font-size: 28px;
            font-weight: 700;
            color: #1E64C8;
            margin-bottom: 20px;
            text-align: center;
        }
        
        .subtitle {
            font-size: 22px;
            font-weight: 600;
            color: #1E64C8;
            margin-bottom: 20px;
            margin-top: 30px;
            border-bottom: 3px solid #1E64C8;
            padding-bottom: 10px;
        }
        
        .stratification-diagram {
            display: flex;
            justify-content: center;
            align-items: center;
            margin-bottom: 20px;
            height: 300px;
            position: relative;
            background: #f8f9fb;
            border-radius: 12px;
            padding: 20px;
        }
        
        .diagram-svg {
            width: 100%;
            height: 100%;
        }
        
        .patient-icon {
            fill: #1E64C8;
            opacity: 0.8;
            animation: fadeIn 0.5s ease-in;
        }
        
        @keyframes fadeIn {
            from { opacity: 0; transform: scale(0.8); }
            to { opacity: 0.8; transform: scale(1); }
        }
        
        .analysis-circle {
            fill: none;
            stroke: #5088d4;
            stroke-width: 3;
            stroke-dasharray: 10,5;
            animation: rotate 10s linear infinite;
            transform-origin: center;
        }
        
        @keyframes rotate {
            from { transform: rotate(0deg); }
            to { transform: rotate(360deg); }
        }
        
        .analysis-core {
            fill: url(#analysisGradient);
            filter: drop-shadow(0 4px 8px rgba(30, 100, 200, 0.3));
        }
        
        .data-stream {
            stroke: #1E64C8;
            stroke-width: 2;
            fill: none;
            opacity: 0.6;
            stroke-dasharray: 5,3;
            animation: dataFlow 2s linear infinite;
        }
        
        @keyframes dataFlow {
            to { stroke-dashoffset: -8; }
        }
        
        .group-high-risk {
            fill: #ff6b6b;
            stroke: white;
            stroke-width: 3;
            filter: drop-shadow(0 4px 8px rgba(255, 107, 107, 0.3));
        }
        
        .group-medium-risk {
            fill: #ffa500;
            stroke: white;
            stroke-width: 3;
            filter: drop-shadow(0 4px 8px rgba(255, 165, 0, 0.3));
        }
        
        .group-low-risk {
            fill: #4CAF50;
            stroke: white;
            stroke-width: 3;
            filter: drop-shadow(0 4px 8px rgba(76, 175, 80, 0.3));
        }
        
        .label-text {
            fill: white;
            font-weight: 700;
            text-anchor: middle;
            pointer-events: none;
        }
        
        .label-subtext {
            fill: white;
            font-size: 11px;
            text-anchor: middle;
            pointer-events: none;
            opacity: 0.95;
        }
        
        .flow-arrow {
            fill: none;
            stroke: #1E64C8;
            stroke-width: 3;
            marker-end: url(#arrowhead);
        }
        
        .biomarker-node {
            fill: white;
            stroke: #1E64C8;
            stroke-width: 2;
        }
        
        .treatment-box {
            fill: white;
            stroke: #1E64C8;
            stroke-width: 2.5;
            rx: 8;
        }
        
        .percentage-label {
            fill: #333;
            font-size: 12px;
            font-weight: 600;
        }
        
        .clustering-visual {
            fill: none;
            stroke: #1E64C8;
            stroke-width: 1;
            stroke-dasharray: 3,2;
            opacity: 0.3;
        }
        
        .content-grid {
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 18px;
            margin-bottom: 18px;
        }
        
        .content-card {
            background: #f8f9fb;
            border-left: 5px solid #1E64C8;
            padding: 16px 20px;
            border-radius: 8px;
            transition: all 0.3s;
        }
        
        .content-card:hover {
            background: #e8f2ff;
            transform: translateX(5px);
        }
        
        .card-header {
            display: flex;
            align-items: center;
            margin-bottom: 10px;
        }
        
        .card-icon {
            font-size: 24px;
            margin-right: 12px;
        }
        
        .card-title {
            font-size: 16px;
            font-weight: 700;
            color: #1E64C8;
        }
        
        .card-content {
            font-size: 14px;
            color: #555;
            line-height: 1.5;
        }
        
        .highlight-box {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 15px 25px;
            border-radius: 10px;
            text-align: center;
            font-size: 15px;
            font-weight: 600;
            box-shadow: 0 4px 15px rgba(102, 126, 234, 0.3);
        }

        /* Detailed section styles */
        .detail-section {
            margin-top: 30px;
            padding: 25px;
            background: #f8f9fb;
            border-radius: 12px;
            border-left: 5px solid #1E64C8;
        }

        .detail-title {
            font-size: 20px;
            font-weight: 700;
            color: #1E64C8;
            margin-bottom: 15px;
            display: flex;
            align-items: center;
        }

        .detail-title-icon {
            font-size: 28px;
            margin-right: 12px;
        }

        .detail-content {
            font-size: 15px;
            color: #333;
            line-height: 1.8;
            margin-bottom: 20px;
        }

        .detail-content p {
            margin-bottom: 12px;
        }

        .detail-content strong {
            color: #1E64C8;
            font-weight: 600;
        }

        .example-box {
            background: white;
            padding: 20px;
            border-radius: 8px;
            margin-top: 15px;
            border: 2px solid #e0e7ff;
        }

        .example-title {
            font-size: 16px;
            font-weight: 700;
            color: #5088d4;
            margin-bottom: 12px;
            display: flex;
            align-items: center;
        }

        .example-icon {
            margin-right: 8px;
        }

        .example-list {
            list-style: none;
            padding-left: 0;
        }

        .example-list li {
            padding: 8px 0 8px 25px;
            position: relative;
            font-size: 14px;
            color: #555;
            line-height: 1.6;
        }

        .example-list li:before {
            content: "‚ñ∏";
            position: absolute;
            left: 5px;
            color: #1E64C8;
            font-weight: bold;
        }

        .key-points {
            background: #fff3cd;
            border-left: 4px solid #ffc107;
            padding: 15px 20px;
            margin: 15px 0;
            border-radius: 4px;
        }

        .key-points-title {
            font-weight: 700;
            color: #856404;
            margin-bottom: 8px;
            font-size: 15px;
        }

        .key-points ul {
            margin-top: 8px;
            padding-left: 20px;
        }

        .key-points li {
            margin-bottom: 6px;
            color: #856404;
            font-size: 14px;
        }

        .method-grid {
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 15px;
            margin-top: 15px;
        }

        .method-card {
            background: white;
            padding: 15px;
            border-radius: 8px;
            border: 2px solid #e0e7ff;
        }

        .method-card-title {
            font-weight: 700;
            color: #1E64C8;
            margin-bottom: 8px;
            font-size: 14px;
        }

        .method-card-content {
            font-size: 13px;
            color: #666;
            line-height: 1.5;
        }

        .visual-diagram {
            background: white;
            padding: 20px;
            border-radius: 8px;
            margin: 20px 0;
            text-align: center;
        }

        .diagram-description {
            font-size: 13px;
            color: #666;
            margin-top: 10px;
            font-style: italic;
        }
    </style>
</head>
<body>
    <!-- Slide 1: Overview -->
    <div class="slide">
        <div class="container">
            <div class="title">Patient Stratification</div>
            
            <div class="stratification-diagram">
                <svg class="diagram-svg" viewBox="0 0 900 280" xmlns="http://www.w3.org/2000/svg">
                    <defs>
                        <linearGradient id="analysisGradient" x1="0%" y1="0%" x2="100%" y2="100%">
                            <stop offset="0%" style="stop-color:#1E64C8;stop-opacity:0.8" />
                            <stop offset="100%" style="stop-color:#5088d4;stop-opacity:0.6" />
                        </linearGradient>
                        <marker id="arrowhead" markerWidth="10" markerHeight="10" refX="9" refY="3" orient="auto">
                            <polygon points="0 0, 10 3, 0 6" fill="#1E64C8" />
                        </marker>
                    </defs>
                    
                    <g transform="translate(120, 140)">
                        <circle cx="0" cy="0" r="80" fill="#e8f2ff" stroke="#1E64C8" stroke-width="2"/>
                        
                        <g>
                            <circle class="patient-icon" cx="-40" cy="-60" r="4" style="animation-delay: 0s"/>
                            <circle class="patient-icon" cx="-20" cy="-60" r="4" style="animation-delay: 0.1s"/>
                            <circle class="patient-icon" cx="0" cy="-60" r="4" style="animation-delay: 0.2s"/>
                            <circle class="patient-icon" cx="20" cy="-60" r="4" style="animation-delay: 0.3s"/>
                            <circle class="patient-icon" cx="40" cy="-60" r="4" style="animation-delay: 0.4s"/>
                            
                            <circle class="patient-icon" cx="-40" cy="-40" r="4" style="animation-delay: 0.5s"/>
                            <circle class="patient-icon" cx="-20" cy="-40" r="4" style="animation-delay: 0.6s"/>
                            <circle class="patient-icon" cx="0" cy="-40" r="4" style="animation-delay: 0.7s"/>
                            <circle class="patient-icon" cx="20" cy="-40" r="4" style="animation-delay: 0.8s"/>
                            <circle class="patient-icon" cx="40" cy="-40" r="4" style="animation-delay: 0.9s"/>
                            
                            <circle class="patient-icon" cx="-40" cy="-20" r="4" style="animation-delay: 1s"/>
                            <circle class="patient-icon" cx="-20" cy="-20" r="4" style="animation-delay: 1.1s"/>
                            <circle class="patient-icon" cx="0" cy="-20" r="4" style="animation-delay: 1.2s"/>
                            <circle class="patient-icon" cx="20" cy="-20" r="4" style="animation-delay: 1.3s"/>
                            <circle class="patient-icon" cx="40" cy="-20" r="4" style="animation-delay: 1.4s"/>
                            
                            <circle class="patient-icon" cx="-40" cy="0" r="4" style="animation-delay: 0.2s"/>
                            <circle class="patient-icon" cx="-20" cy="0" r="4" style="animation-delay: 0.3s"/>
                            <circle class="patient-icon" cx="0" cy="0" r="4" style="animation-delay: 0.4s"/>
                            <circle class="patient-icon" cx="20" cy="0" r="4" style="animation-delay: 0.5s"/>
                            <circle class="patient-icon" cx="40" cy="0" r="4" style="animation-delay: 0.6s"/>
                            
                            <circle class="patient-icon" cx="-40" cy="20" r="4" style="animation-delay: 0.7s"/>
                            <circle class="patient-icon" cx="-20" cy="20" r="4" style="animation-delay: 0.8s"/>
                            <circle class="patient-icon" cx="0" cy="20" r="4" style="animation-delay: 0.9s"/>
                            <circle class="patient-icon" cx="20" cy="20" r="4" style="animation-delay: 1s"/>
                            <circle class="patient-icon" cx="40" cy="20" r="4" style="animation-delay: 1.1s"/>
                            
                            <circle class="patient-icon" cx="-40" cy="40" r="4" style="animation-delay: 1.2s"/>
                            <circle class="patient-icon" cx="-20" cy="40" r="4" style="animation-delay: 1.3s"/>
                            <circle class="patient-icon" cx="0" cy="40" r="4" style="animation-delay: 1.4s"/>
                            <circle class="patient-icon" cx="20" cy="40" r="4" style="animation-delay: 1.5s"/>
                            <circle class="patient-icon" cx="40" cy="40" r="4" style="animation-delay: 1.6s"/>
                        </g>
                        
                        <text class="label-text" x="0" y="75" font-size="16" fill="#1E64C8">Patient</text>
                        <text class="label-text" x="0" y="95" font-size="16" fill="#1E64C8">Population</text>
                        <text class="percentage-label" x="0" y="-95">n = 1000</text>
                    </g>
                    
                    <path class="data-stream" d="M180,140 L280,140"/>
                    <path class="data-stream" d="M180,100 L280,100"/>
                    <path class="data-stream" d="M180,180 L280,180"/>
                    
                    <g transform="translate(350, 140)">
                        <circle class="analysis-circle" cx="0" cy="0" r="55"/>
                        <circle class="analysis-core" cx="0" cy="0" r="50"/>
                        
                        <circle class="biomarker-node" cx="-20" cy="-20" r="8"/>
                        <text x="-20" y="-18" font-size="10" text-anchor="middle" fill="#1E64C8">B1</text>
                        
                        <circle class="biomarker-node" cx="20" cy="-20" r="8"/>
                        <text x="20" y="-18" font-size="10" text-anchor="middle" fill="#1E64C8">B2</text>
                        
                        <circle class="biomarker-node" cx="0" cy="20" r="8"/>
                        <text x="0" y="22" font-size="10" text-anchor="middle" fill="#1E64C8">B3</text>
                        
                        <line x1="-20" y1="-20" x2="20" y2="-20" stroke="#1E64C8" stroke-width="1" opacity="0.5"/>
                        <line x1="-20" y1="-20" x2="0" y2="20" stroke="#1E64C8" stroke-width="1" opacity="0.5"/>
                        <line x1="20" y1="-20" x2="0" y2="20" stroke="#1E64C8" stroke-width="1" opacity="0.5"/>
                        
                        <text class="label-text" x="0" y="0" font-size="14">Biomarker</text>
                        <text class="label-text" x="0" y="15" font-size="14">Analysis</text>
                        
                        <text x="0" y="-75" font-size="20" text-anchor="middle">üî¨</text>
                    </g>
                    
                    <path class="flow-arrow" d="M400,110 L500,70"/>
                    <path class="flow-arrow" d="M400,140 L500,140"/>
                    <path class="flow-arrow" d="M400,170 L500,210"/>
                    
                    <g transform="translate(550, 60)">
                        <rect class="group-high-risk" x="-60" y="-25" width="120" height="50" rx="8"/>
                        
                        <circle class="clustering-visual" cx="0" cy="0" r="35"/>
                        <circle cx="-20" cy="-5" r="3" fill="white" opacity="0.9"/>
                        <circle cx="-10" cy="0" r="3" fill="white" opacity="0.9"/>
                        <circle cx="0" cy="-3" r="3" fill="white" opacity="0.9"/>
                        <circle cx="10" cy="2" r="3" fill="white" opacity="0.9"/>
                        <circle cx="20" cy="-2" r="3" fill="white" opacity="0.9"/>
                        
                        <text class="label-text" x="0" y="0" font-size="15">High Risk</text>
                        <text class="label-subtext" x="0" y="15" font-size="12">Intensive therapy</text>
                        <text class="percentage-label" x="0" y="-35">20% (n=200)</text>
                    </g>
                    
                    <g transform="translate(550, 140)">
                        <rect class="group-medium-risk" x="-60" y="-25" width="120" height="50" rx="8"/>
                        
                        <circle cx="-20" cy="-5" r="3" fill="white" opacity="0.9"/>
                        <circle cx="-10" cy="0" r="3" fill="white" opacity="0.9"/>
                        <circle cx="0" cy="-3" r="3" fill="white" opacity="0.9"/>
                        <circle cx="10" cy="2" r="3" fill="white" opacity="0.9"/>
                        <circle cx="20" cy="-2" r="3" fill="white" opacity="0.9"/>
                        <circle cx="-15" cy="5" r="3" fill="white" opacity="0.9"/>
                        <circle cx="15" cy="8" r="3" fill="white" opacity="0.9"/>
                        
                        <text class="label-text" x="0" y="0" font-size="15">Medium Risk</text>
                        <text class="label-subtext" x="0" y="15" font-size="12">Standard therapy</text>
                        <text class="percentage-label" x="0" y="-35">50% (n=500)</text>
                    </g>
                    
                    <g transform="translate(550, 220)">
                        <rect class="group-low-risk" x="-60" y="-25" width="120" height="50" rx="8"/>
                        
                        <circle cx="-20" cy="-5" r="3" fill="white" opacity="0.9"/>
                        <circle cx="-10" cy="0" r="3" fill="white" opacity="0.9"/>
                        <circle cx="0" cy="-3" r="3" fill="white" opacity="0.9"/>
                        <circle cx="10" cy="2" r="3" fill="white" opacity="0.9"/>
                        
                        <text class="label-text" x="0" y="0" font-size="15">Low Risk</text>
                        <text class="label-subtext" x="0" y="15" font-size="12">Observation</text>
                        <text class="percentage-label" x="0" y="-35">30% (n=300)</text>
                    </g>
                    
                    <path class="flow-arrow" d="M610,70 L700,100"/>
                    <path class="flow-arrow" d="M610,140 L700,135"/>
                    <path class="flow-arrow" d="M610,210 L700,170"/>
                    
                    <g transform="translate(750, 140)">
                        <rect class="treatment-box" x="-65" y="-35" width="130" height="70"/>
                        <text class="label-text" x="0" y="-10" font-size="14" fill="#1E64C8">Treatment</text>
                        <text class="label-text" x="0" y="5" font-size="14" fill="#1E64C8">Assignment</text>
                        <text class="label-subtext" x="0" y="20" font-size="11" fill="#5088d4">Personalized approach</text>
                        
                        <text x="0" y="-50" font-size="24" text-anchor="middle">üíä</text>
                    </g>
                    
                    <text x="120" y="230" font-size="24" text-anchor="middle">üë•</text>
                    <text x="350" y="220" font-size="24" text-anchor="middle">üìä</text>
                </svg>
            </div>
            
            <div class="content-grid">
                <div class="content-card">
                    <div class="card-header">
                        <div class="card-icon">üéØ</div>
                        <div class="card-title">Subgroup Identification</div>
                    </div>
                    <div class="card-content">
                        Clustering and classification to define patient groups
                    </div>
                </div>
                
                <div class="content-card">
                    <div class="card-header">
                        <div class="card-icon">üìä</div>
                        <div class="card-title">Risk Groups</div>
                    </div>
                    <div class="card-content">
                        Stratify patients by disease risk or prognosis
                    </div>
                </div>
                
                <div class="content-card">
                    <div class="card-header">
                        <div class="card-icon">üíä</div>
                        <div class="card-title">Treatment Assignment</div>
                    </div>
                    <div class="card-content">
                        Match therapies to molecular profiles
                    </div>
                </div>
                
                <div class="content-card">
                    <div class="card-header">
                        <div class="card-icon">‚ú®</div>
                        <div class="card-title">Enrichment Strategies</div>
                    </div>
                    <div class="card-content">
                        Select patients likely to benefit from intervention
                    </div>
                </div>
            </div>
            
            <div class="highlight-box">
                Adaptive Designs: Trial designs that evolve based on accumulating biomarker data
            </div>
        </div>
    </div>

    <!-- Slide 2: Subgroup Identification -->
    <div class="slide">
        <div class="container">
            <div class="title">1. Subgroup Identification üéØ</div>
            
            <div class="detail-section">
                <div class="detail-title">
                    <span class="detail-title-icon">üîç</span>
                    What is Subgroup Identification?
                </div>
                <div class="detail-content">
                    <p>Subgroup identification is the process of discovering and defining distinct patient populations within a larger heterogeneous cohort based on shared biological, clinical, or molecular characteristics. This approach recognizes that patients with the same diagnosis may have fundamentally different disease mechanisms requiring tailored therapeutic approaches.</p>
                    
                    <p><strong>Core Principle:</strong> Not all patients with the same disease label respond identically to treatment. By identifying molecular and phenotypic subtypes, we can optimize therapeutic strategies for each subgroup.</p>
                </div>

                <div class="key-points">
                    <div class="key-points-title">üéØ Key Objectives</div>
                    <ul>
                        <li>Discover biologically distinct patient subpopulations</li>
                        <li>Identify predictive biomarkers for treatment response</li>
                        <li>Enable precision medicine approaches</li>
                        <li>Improve clinical trial efficiency and success rates</li>
                    </ul>
                </div>

                <div class="visual-diagram">
                    <svg width="800" height="300" viewBox="0 0 800 300">
                        <defs>
                            <linearGradient id="grad1" x1="0%" y1="0%" x2="100%" y2="0%">
                                <stop offset="0%" style="stop-color:#1E64C8;stop-opacity:1" />
                                <stop offset="100%" style="stop-color:#5088d4;stop-opacity:1" />
                            </linearGradient>
                        </defs>
                        
                        <!-- Heterogeneous population -->
                        <g transform="translate(100, 150)">
                            <circle cx="0" cy="0" r="70" fill="#e8f2ff" stroke="#1E64C8" stroke-width="2"/>
                            <circle cx="-30" cy="-20" r="5" fill="#ff6b6b"/>
                            <circle cx="-20" cy="10" r="5" fill="#4CAF50"/>
                            <circle cx="0" cy="-30" r="5" fill="#ffa500"/>
                            <circle cx="15" cy="-15" r="5" fill="#ff6b6b"/>
                            <circle cx="25" cy="15" r="5" fill="#4CAF50"/>
                            <circle cx="-10" cy="25" r="5" fill="#ffa500"/>
                            <circle cx="30" cy="-5" r="5" fill="#ff6b6b"/>
                            <circle cx="-25" cy="-5" r="5" fill="#4CAF50"/>
                            <circle cx="10" cy="20" r="5" fill="#ffa500"/>
                            <circle cx="-15" cy="-35" r="5" fill="#ff6b6b"/>
                            <text x="0" y="100" text-anchor="middle" font-size="14" font-weight="700" fill="#1E64C8">Heterogeneous</text>
                            <text x="0" y="115" text-anchor="middle" font-size="14" font-weight="700" fill="#1E64C8">Population</text>
                        </g>

                        <!-- Arrow -->
                        <path d="M180,150 L280,150" stroke="#1E64C8" stroke-width="3" fill="none" marker-end="url(#arrow2)"/>
                        <text x="230" y="140" text-anchor="middle" font-size="13" fill="#1E64C8" font-weight="600">Clustering</text>
                        
                        <defs>
                            <marker id="arrow2" markerWidth="10" markerHeight="10" refX="9" refY="3" orient="auto">
                                <polygon points="0 0, 10 3, 0 6" fill="#1E64C8" />
                            </marker>
                        </defs>

                        <!-- Subgroup A (High risk) -->
                        <g transform="translate(400, 80)">
                            <ellipse cx="0" cy="0" rx="60" ry="45" fill="#ffe0e0" stroke="#ff6b6b" stroke-width="2" stroke-dasharray="5,3"/>
                            <circle cx="-20" cy="-10" r="5" fill="#ff6b6b"/>
                            <circle cx="10" cy="-5" r="5" fill="#ff6b6b"/>
                            <circle cx="-10" cy="10" r="5" fill="#ff6b6b"/>
                            <circle cx="15" cy="5" r="5" fill="#ff6b6b"/>
                            <text x="0" y="60" text-anchor="middle" font-size="12" font-weight="700" fill="#ff6b6b">Subgroup A</text>
                            <text x="0" y="73" text-anchor="middle" font-size="11" fill="#d63031">(High Expression)</text>
                        </g>

                        <!-- Subgroup B (Medium risk) -->
                        <g transform="translate(400, 170)">
                            <ellipse cx="0" cy="0" rx="60" ry="45" fill="#fff3e0" stroke="#ffa500" stroke-width="2" stroke-dasharray="5,3"/>
                            <circle cx="-20" cy="-10" r="5" fill="#ffa500"/>
                            <circle cx="10" cy="-5" r="5" fill="#ffa500"/>
                            <circle cx="-10" cy="10" r="5" fill="#ffa500"/>
                            <circle cx="15" cy="5" r="5" fill="#ffa500"/>
                            <text x="0" y="60" text-anchor="middle" font-size="12" font-weight="700" fill="#ffa500">Subgroup B</text>
                            <text x="0" y="73" text-anchor="middle" font-size="11" fill="#e67e00">(Medium Expression)</text>
                        </g>

                        <!-- Subgroup C (Low risk) -->
                        <g transform="translate(400, 260)">
                            <ellipse cx="0" cy="0" rx="60" ry="40" fill="#e8f5e9" stroke="#4CAF50" stroke-width="2" stroke-dasharray="5,3"/>
                            <circle cx="-20" cy="-10" r="5" fill="#4CAF50"/>
                            <circle cx="10" cy="-5" r="5" fill="#4CAF50"/>
                            <circle cx="-10" cy="5" r="5" fill="#4CAF50"/>
                            <text x="0" y="-50" text-anchor="middle" font-size="12" font-weight="700" fill="#4CAF50">Subgroup C</text>
                            <text x="0" y="-38" text-anchor="middle" font-size="11" fill="#2e7d32">(Low Expression)</text>
                        </g>

                        <!-- Characteristics -->
                        <g transform="translate(550, 100)">
                            <rect x="0" y="0" width="220" height="160" fill="white" stroke="#1E64C8" stroke-width="2" rx="8"/>
                            <text x="110" y="25" text-anchor="middle" font-size="14" font-weight="700" fill="#1E64C8">Subgroup Features</text>
                            <line x1="10" y1="35" x2="210" y2="35" stroke="#e0e7ff" stroke-width="1"/>
                            
                            <text x="15" y="55" font-size="12" fill="#ff6b6b" font-weight="700">‚óè Subgroup A:</text>
                            <text x="20" y="70" font-size="11" fill="#555">- High biomarker level</text>
                            <text x="20" y="82" font-size="11" fill="#555">- Aggressive phenotype</text>
                            
                            <text x="15" y="105" font-size="12" fill="#ffa500" font-weight="700">‚óè Subgroup B:</text>
                            <text x="20" y="120" font-size="11" fill="#555">- Moderate levels</text>
                            <text x="20" y="132" font-size="11" fill="#555">- Standard response</text>
                            
                            <text x="15" y="155" font-size="12" fill="#4CAF50" font-weight="700">‚óè Subgroup C:</text>
                            <text x="20" y="-125" font-size="11" fill="#555">- Low expression</text>
                            <text x="20" y="-113" font-size="11" fill="#555">- Good prognosis</text>
                        </g>
                    </svg>
                    <div class="diagram-description">
                        Figure 1: Transformation of heterogeneous patient population into distinct molecular subgroups
                    </div>
                </div>

                <div class="method-grid">
                    <div class="method-card">
                        <div class="method-card-title">üß¨ Unsupervised Clustering</div>
                        <div class="method-card-content">
                            <strong>Methods:</strong> K-means, hierarchical clustering, consensus clustering
                            <br><strong>Data:</strong> Gene expression, genomic mutations, multi-omics profiles
                            <br><strong>Output:</strong> Natural groupings without predefined labels
                        </div>
                    </div>

                    <div class="method-card">
                        <div class="method-card-title">üéØ Supervised Classification</div>
                        <div class="method-card-content">
                            <strong>Methods:</strong> Random forests, SVM, neural networks
                            <br><strong>Data:</strong> Labeled training data with known outcomes
                            <br><strong>Output:</strong> Predictive models for subgroup assignment
                        </div>
                    </div>

                    <div class="method-card">
                        <div class="method-card-title">üìä Pathway Analysis</div>
                        <div class="method-card-content">
                            <strong>Methods:</strong> GSEA, pathway enrichment, network analysis
                            <br><strong>Data:</strong> Gene sets, signaling pathways, biological networks
                            <br><strong>Output:</strong> Mechanistically distinct subgroups
                        </div>
                    </div>

                    <div class="method-card">
                        <div class="method-card-title">üî¨ Biomarker-Driven</div>
                        <div class="method-card-content">
                            <strong>Methods:</strong> Threshold-based stratification, composite scores
                            <br><strong>Data:</strong> Specific biomarkers (e.g., HER2, EGFR, PD-L1)
                            <br><strong>Output:</strong> Clinically actionable subgroups
                        </div>
                    </div>
                </div>

                <div class="example-box">
                    <div class="example-title">
                        <span class="example-icon">üí°</span>
                        Clinical Example: Breast Cancer Molecular Subtypes
                    </div>
                    <ul class="example-list">
                        <li><strong>Luminal A:</strong> ER+/PR+, HER2-, low Ki-67 ‚Üí Excellent prognosis, hormone therapy responsive</li>
                        <li><strong>Luminal B:</strong> ER+/PR+/-, HER2+/-, high Ki-67 ‚Üí Intermediate prognosis, may need chemotherapy</li>
                        <li><strong>HER2-enriched:</strong> ER-, PR-, HER2+ ‚Üí Responds to anti-HER2 targeted therapy (trastuzumab)</li>
                        <li><strong>Triple-negative/Basal-like:</strong> ER-, PR-, HER2- ‚Üí Aggressive, requires chemotherapy</li>
                    </ul>
                </div>
            </div>
        </div>
    </div>

    <!-- Slide 3: Risk Groups -->
    <div class="slide">
        <div class="container">
            <div class="title">2. Risk Groups üìä</div>
            
            <div class="detail-section">
                <div class="detail-title">
                    <span class="detail-title-icon">‚öñÔ∏è</span>
                    What are Risk Groups?
                </div>
                <div class="detail-content">
                    <p>Risk stratification is the systematic classification of patients into categories based on their probability of experiencing adverse outcomes, disease progression, or treatment complications. This approach enables clinicians to match the intensity of intervention to the level of risk, avoiding both under-treatment and over-treatment.</p>
                    
                    <p><strong>Core Principle:</strong> Different patients have different baseline risks and prognoses. By accurately stratifying risk, we can optimize resource allocation, intensify treatment for high-risk patients, and spare low-risk patients from unnecessary toxicity.</p>
                </div>

                <div class="key-points">
                    <div class="key-points-title">üìà Risk Stratification Goals</div>
                    <ul>
                        <li>Predict disease-free survival and overall survival</li>
                        <li>Estimate probability of recurrence or metastasis</li>
                        <li>Guide treatment intensity decisions</li>
                        <li>Inform surveillance and monitoring strategies</li>
                        <li>Enable personalized prognostic counseling</li>
                    </ul>
                </div>

                <div class="visual-diagram">
                    <svg width="800" height="350" viewBox="0 0 800 350">
                        <!-- Risk Pyramid -->
                        <g transform="translate(200, 50)">
                            <!-- High Risk - Top -->
                            <polygon points="0,0 -80,80 80,80" fill="#ff6b6b" opacity="0.8" stroke="white" stroke-width="3"/>
                            <text x="0" y="45" text-anchor="middle" font-size="15" font-weight="700" fill="white">HIGH RISK</text>
                            <text x="0" y="62" text-anchor="middle" font-size="12" fill="white">20% of patients</text>
                            
                            <!-- Medium Risk - Middle -->
                            <polygon points="-80,80 80,80 120,160 -120,160" fill="#ffa500" opacity="0.8" stroke="white" stroke-width="3"/>
                            <text x="0" y="115" text-anchor="middle" font-size="15" font-weight="700" fill="white">MEDIUM RISK</text>
                            <text x="0" y="132" text-anchor="middle" font-size="12" fill="white">50% of patients</text>
                            
                            <!-- Low Risk - Bottom -->
                            <polygon points="-120,160 120,160 150,220 -150,220" fill="#4CAF50" opacity="0.8" stroke="white" stroke-width="3"/>
                            <text x="0" y="188" text-anchor="middle" font-size="15" font-weight="700" fill="white">LOW RISK</text>
                            <text x="0" y="205" text-anchor="middle" font-size="12" fill="white">30% of patients</text>
                            
                            <text x="0" y="250" text-anchor="middle" font-size="14" font-weight="700" fill="#1E64C8">Risk Pyramid</text>
                        </g>

                        <!-- Risk Factors -->
                        <g transform="translate(480, 80)">
                            <rect x="0" y="0" width="280" height="240" fill="white" stroke="#1E64C8" stroke-width="2" rx="8"/>
                            <text x="140" y="25" text-anchor="middle" font-size="14" font-weight="700" fill="#1E64C8">Risk Stratification Factors</text>
                            <line x1="10" y1="35" x2="270" y2="35" stroke="#e0e7ff" stroke-width="1"/>
                            
                            <!-- Clinical Factors -->
                            <text x="15" y="55" font-size="13" fill="#1E64C8" font-weight="700">üìã Clinical Factors</text>
                            <text x="20" y="72" font-size="11" fill="#555">‚Ä¢ Age, performance status</text>
                            <text x="20" y="86" font-size="11" fill="#555">‚Ä¢ Disease stage, tumor size</text>
                            <text x="20" y="100" font-size="11" fill="#555">‚Ä¢ Comorbidities, prior treatment</text>
                            
                            <!-- Molecular Factors -->
                            <text x="15" y="125" font-size="13" fill="#1E64C8" font-weight="700">üß¨ Molecular Factors</text>
                            <text x="20" y="142" font-size="11" fill="#555">‚Ä¢ Genetic mutations (TP53, KRAS)</text>
                            <text x="20" y="156" font-size="11" fill="#555">‚Ä¢ Gene expression signatures</text>
                            <text x="20" y="170" font-size="11" fill="#555">‚Ä¢ Chromosomal abnormalities</text>
                            
                            <!-- Laboratory Markers -->
                            <text x="15" y="195" font-size="13" fill="#1E64C8" font-weight="700">üî¨ Laboratory Markers</text>
                            <text x="20" y="212" font-size="11" fill="#555">‚Ä¢ Tumor markers (PSA, CEA, CA-125)</text>
                            <text x="20" y="226" font-size="11" fill="#555">‚Ä¢ Inflammatory markers (CRP, LDH)</text>
                        </g>

                        <!-- Survival Curves -->
                        <g transform="translate(50, 310)">
                            <text x="100" y="-10" text-anchor="middle" font-size="12" font-weight="700" fill="#1E64C8">Survival by Risk Group</text>
                            <!-- Axes -->
                            <line x1="0" y1="0" x2="0" y2="-80" stroke="#333" stroke-width="2"/>
                            <line x1="0" y1="0" x2="200" y2="0" stroke="#333" stroke-width="2"/>
                            <text x="-10" y="-75" font-size="10" fill="#333">100%</text>
                            <text x="-10" y="5" font-size="10" fill="#333">0%</text>
                            <text x="200" y="15" font-size="10" fill="#333">Time</text>
                            
                            <!-- Low risk curve -->
                            <path d="M0,-75 Q50,-73 100,-70 T200,-65" stroke="#4CAF50" stroke-width="3" fill="none"/>
                            <text x="205" y="-62" font-size="10" fill="#4CAF50" font-weight="600">Low</text>
                            
                            <!-- Medium risk curve -->
                            <path d="M0,-75 Q50,-65 100,-55 T200,-40" stroke="#ffa500" stroke-width="3" fill="none"/>
                            <text x="205" y="-37" font-size="10" fill="#ffa500" font-weight="600">Medium</text>
                            
                            <!-- High risk curve -->
                            <path d="M0,-75 Q50,-50 100,-35 T200,-15" stroke="#ff6b6b" stroke-width="3" fill="none"/>
                            <text x="205" y="-12" font-size="10" fill="#ff6b6b" font-weight="600">High</text>
                        </g>
                    </svg>
                    <div class="diagram-description">
                        Figure 2: Risk stratification pyramid and corresponding survival outcomes
                    </div>
                </div>

                <div class="method-grid">
                    <div class="method-card">
                        <div class="method-card-title">üìê Scoring Systems</div>
                        <div class="method-card-content">
                            <strong>Examples:</strong> APACHE, GRACE, CHA‚ÇÇDS‚ÇÇ-VASc
                            <br><strong>Approach:</strong> Weighted sum of clinical variables
                            <br><strong>Advantage:</strong> Simple, interpretable, widely validated
                        </div>
                    </div>

                    <div class="method-card">
                        <div class="method-card-title">üéØ Nomograms</div>
                        <div class="method-card-content">
                            <strong>Examples:</strong> Memorial Sloan Kettering nomograms
                            <br><strong>Approach:</strong> Graphical regression models
                            <br><strong>Advantage:</strong> Individualized risk prediction
                        </div>
                    </div>

                    <div class="method-card">
                        <div class="method-card-title">üß¨ Molecular Signatures</div>
                        <div class="method-card-content">
                            <strong>Examples:</strong> Oncotype DX, MammaPrint, Decipher
                            <br><strong>Approach:</strong> Multi-gene expression panels
                            <br><strong>Advantage:</strong> Biological insight, high accuracy
                        </div>
                    </div>

                    <div class="method-card">
                        <div class="method-card-title">ü§ñ Machine Learning Models</div>
                        <div class="method-card-content">
                            <strong>Methods:</strong> Cox regression, random survival forests, deep learning
                            <br><strong>Approach:</strong> Integrate complex multi-dimensional data
                            <br><strong>Advantage:</strong> Handle non-linear relationships
                        </div>
                    </div>
                </div>

                <div class="example-box">
                    <div class="example-title">
                        <span class="example-icon">üí°</span>
                        Clinical Example: Prostate Cancer Risk Stratification (D'Amico Classification)
                    </div>
                    <ul class="example-list">
                        <li><strong>Low Risk:</strong> PSA ‚â§10 ng/mL AND Gleason score ‚â§6 AND stage T1c-T2a
                            <br>‚Üí Treatment: Active surveillance or focal therapy</li>
                        <li><strong>Intermediate Risk:</strong> PSA 10-20 ng/mL OR Gleason score 7 OR stage T2b
                            <br>‚Üí Treatment: Radiation + short-term hormone therapy OR surgery</li>
                        <li><strong>High Risk:</strong> PSA >20 ng/mL OR Gleason score 8-10 OR stage ‚â•T2c
                            <br>‚Üí Treatment: Radiation + long-term hormone therapy + chemotherapy</li>
                    </ul>
                </div>
            </div>
        </div>
    </div>

    <!-- Slide 4: Treatment Assignment -->
    <div class="slide">
        <div class="container">
            <div class="title">3. Treatment Assignment üíä</div>
            
            <div class="detail-section">
                <div class="detail-title">
                    <span class="detail-title-icon">üéØ</span>
                    What is Treatment Assignment?
                </div>
                <div class="detail-content">
                    <p>Treatment assignment is the precision medicine approach of matching specific therapeutic interventions to individual patients or patient subgroups based on their unique molecular, genetic, and clinical profiles. This strategy moves beyond one-size-fits-all protocols to deliver personalized treatment plans that maximize efficacy while minimizing toxicity.</p>
                    
                    <p><strong>Core Principle:</strong> The right treatment for the right patient at the right time. By matching therapies to the underlying molecular drivers of disease, we can dramatically improve response rates and reduce unnecessary adverse effects from ineffective treatments.</p>
                </div>

                <div class="key-points">
                    <div class="key-points-title">üéØ Treatment Selection Objectives</div>
                    <ul>
                        <li>Match targeted therapies to actionable biomarkers</li>
                        <li>Predict treatment response and toxicity</li>
                        <li>Optimize drug-target engagement</li>
                        <li>Avoid treatments likely to be ineffective</li>
                        <li>Sequence therapies based on resistance mechanisms</li>
                    </ul>
                </div>

                <div class="visual-diagram">
                    <svg width="800" height="380" viewBox="0 0 800 380">
                        <!-- Patient Assessment -->
                        <g transform="translate(100, 100)">
                            <circle cx="0" cy="0" r="55" fill="#e8f2ff" stroke="#1E64C8" stroke-width="3"/>
                            <text x="0" y="-65" text-anchor="middle" font-size="14" font-weight="700" fill="#1E64C8">Patient</text>
                            <text x="0" y="-50" text-anchor="middle" font-size="12" fill="#1E64C8">Assessment</text>
                            
                            <!-- Patient icon -->
                            <text x="0" y="-5" text-anchor="middle" font-size="30">üë§</text>
                            
                            <!-- Assessment points -->
                            <circle cx="-35" cy="0" r="8" fill="#1E64C8"/>
                            <text x="-35" y="3" text-anchor="middle" font-size="8" fill="white" font-weight="700">DNA</text>
                            
                            <circle cx="35" cy="0" r="8" fill="#1E64C8"/>
                            <text x="35" y="3" text-anchor="middle" font-size="8" fill="white" font-weight="700">RNA</text>
                            
                            <circle cx="0" cy="35" r="8" fill="#1E64C8"/>
                            <text x="0" y="38" text-anchor="middle" font-size="7" fill="white" font-weight="700">Prot</text>
                        </g>

                        <!-- Biomarker Testing -->
                        <g transform="translate(250, 100)">
                            <rect x="-65" y="-45" width="130" height="90" fill="white" stroke="#1E64C8" stroke-width="2" rx="8"/>
                            <text x="0" y="-55" text-anchor="middle" font-size="12" font-weight="700" fill="#1E64C8">Molecular Testing</text>
                            
                            <text x="0" y="-20" text-anchor="middle" font-size="11" fill="#555" font-weight="600">Biomarker Profile:</text>
                            <text x="0" y="0" text-anchor="middle" font-size="10" fill="#ff6b6b">EGFR: Mutation (+)</text>
                            <text x="0" y="15" text-anchor="middle" font-size="10" fill="#4CAF50">ALK: Fusion (-)</text>
                            <text x="0" y="30" text-anchor="middle" font-size="10" fill="#ffa500">PD-L1: 60% TPS</text>
                        </g>

                        <!-- Decision Algorithm -->
                        <g transform="translate(400, 100)">
                            <polygon points="0,-40 30,0 0,40 -30,0" fill="#667eea" stroke="white" stroke-width="2"/>
                            <text x="0" y="5" text-anchor="middle" font-size="12" fill="white" font-weight="700">Decision</text>
                            <text x="0" y="-55" text-anchor="middle" font-size="12" font-weight="700" fill="#1E64C8">Algorithm</text>
                        </g>

                        <!-- Treatment Options -->
                        <!-- Option 1: Targeted Therapy -->
                        <g transform="translate(550, 50)">
                            <rect x="-75" y="-30" width="150" height="60" fill="#ffe0e0" stroke="#ff6b6b" stroke-width="2" rx="8"/>
                            <text x="0" y="-5" text-anchor="middle" font-size="12" fill="#d63031" font-weight="700">üéØ Targeted Therapy</text>
                            <text x="0" y="10" text-anchor="middle" font-size="10" fill="#555">EGFR Inhibitor</text>
                            <text x="0" y="22" text-anchor="middle" font-size="9" fill="#555">(Osimertinib)</text>
                        </g>

                        <!-- Option 2: Immunotherapy -->
                        <g transform="translate(550, 140)">
                            <rect x="-75" y="-30" width="150" height="60" fill="#fff3e0" stroke="#ffa500" stroke-width="2" rx="8"/>
                            <text x="0" y="-5" text-anchor="middle" font-size="12" fill="#e67e00" font-weight="700">üíâ Immunotherapy</text>
                            <text x="0" y="10" text-anchor="middle" font-size="10" fill="#555">PD-1 Inhibitor</text>
                            <text x="0" y="22" text-anchor="middle" font-size="9" fill="#555">(Pembrolizumab)</text>
                        </g>

                        <!-- Option 3: Combination -->
                        <g transform="translate(550, 230)">
                            <rect x="-75" y="-30" width="150" height="60" fill="#e8f5e9" stroke="#4CAF50" stroke-width="2" rx="8"/>
                            <text x="0" y="-5" text-anchor="middle" font-size="12" fill="#2e7d32" font-weight="700">üîÑ Combination</text>
                            <text x="0" y="10" text-anchor="middle" font-size="10" fill="#555">Targeted + Chemo</text>
                            <text x="0" y="22" text-anchor="middle" font-size="9" fill="#555">(Based on stage)</text>
                        </g>

                        <!-- Arrows -->
                        <path d="M155,100 L185,100" stroke="#1E64C8" stroke-width="2" marker-end="url(#arrow3)"/>
                        <path d="M315,100 L370,100" stroke="#1E64C8" stroke-width="2" marker-end="url(#arrow3)"/>
                        <path d="M430,85 L475,55" stroke="#ff6b6b" stroke-width="2" marker-end="url(#arrow3)"/>
                        <path d="M430,100 L475,140" stroke="#ffa500" stroke-width="2" marker-end="url(#arrow3)"/>
                        <path d="M430,115 L475,225" stroke="#4CAF50" stroke-width="2" marker-end="url(#arrow3)"/>
                        
                        <defs>
                            <marker id="arrow3" markerWidth="10" markerHeight="10" refX="9" refY="3" orient="auto">
                                <polygon points="0 0, 10 3, 0 6" fill="#1E64C8" />
                            </marker>
                        </defs>

                        <!-- Outcome Monitoring -->
                        <g transform="translate(400, 320)">
                            <rect x="-150" y="-25" width="300" height="50" fill="#f0f7ff" stroke="#1E64C8" stroke-width="2" rx="8"/>
                            <text x="0" y="-5" text-anchor="middle" font-size="12" fill="#1E64C8" font-weight="700">üìä Response Monitoring & Adaptation</text>
                            <text x="0" y="10" text-anchor="middle" font-size="10" fill="#555">Re-biopsy if progression ‚Üí Resistance mechanism ‚Üí Switch therapy</text>
                        </g>
                    </svg>
                    <div class="diagram-description">
                        Figure 3: Biomarker-driven treatment assignment workflow
                    </div>
                </div>

                <div class="method-grid">
                    <div class="method-card">
                        <div class="method-card-title">üß¨ Genomic Matching</div>
                        <div class="method-card-content">
                            <strong>Approach:</strong> Identify actionable mutations
                            <br><strong>Examples:</strong> EGFR mutations ‚Üí EGFR-TKIs, BRAF V600E ‚Üí BRAF inhibitors
                            <br><strong>Tools:</strong> Next-generation sequencing, liquid biopsy
                        </div>
                    </div>

                    <div class="method-card">
                        <div class="method-card-title">üéØ Protein Biomarkers</div>
                        <div class="method-card-content">
                            <strong>Approach:</strong> Target overexpressed proteins
                            <br><strong>Examples:</strong> HER2+ ‚Üí Trastuzumab, PD-L1+ ‚Üí Immunotherapy
                            <br><strong>Tools:</strong> IHC, flow cytometry, mass spectrometry
                        </div>
                    </div>

                    <div class="method-card">
                        <div class="method-card-title">üìä Expression Signatures</div>
                        <div class="method-card-content">
                            <strong>Approach:</strong> Multi-gene predictive models
                            <br><strong>Examples:</strong> Oncotype DX for chemotherapy benefit
                            <br><strong>Tools:</strong> Gene expression profiling, RNA-seq
                        </div>
                    </div>

                    <div class="method-card">
                        <div class="method-card-title">üî¨ Functional Testing</div>
                        <div class="method-card-content">
                            <strong>Approach:</strong> Test drug sensitivity ex vivo
                            <br><strong>Examples:</strong> Organoid drug screening, PDX models
                            <br><strong>Tools:</strong> 3D culture systems, patient-derived models
                        </div>
                    </div>
                </div>

                <div class="example-box">
                    <div class="example-title">
                        <span class="example-icon">üí°</span>
                        Clinical Example: Non-Small Cell Lung Cancer (NSCLC) Treatment Assignment
                    </div>
                    <ul class="example-list">
                        <li><strong>EGFR Mutation Positive:</strong> First-line osimertinib (3rd generation EGFR-TKI)
                            <br>‚Üí Response rate: 80%, PFS: 18 months vs 10 months with chemotherapy</li>
                        <li><strong>ALK Rearrangement Positive:</strong> First-line alectinib (ALK inhibitor)
                            <br>‚Üí Superior CNS penetration, PFS: 34 months vs 11 months with chemotherapy</li>
                        <li><strong>PD-L1 ‚â•50%, No Driver Mutations:</strong> First-line pembrolizumab (PD-1 inhibitor)
                            <br>‚Üí OS benefit: 20 months vs 12 months with chemotherapy</li>
                        <li><strong>No Actionable Alterations:</strong> Platinum-based chemotherapy ¬± immunotherapy
                            <br>‚Üí Standard approach when targeted options not available</li>
                    </ul>
                </div>
            </div>
        </div>
    </div>

    <!-- Slide 5: Enrichment Strategies -->
    <div class="slide">
        <div class="container">
            <div class="title">4. Enrichment Strategies ‚ú®</div>
            
            <div class="detail-section">
                <div class="detail-title">
                    <span class="detail-title-icon">üîç</span>
                    What are Enrichment Strategies?
                </div>
                <div class="detail-content">
                    <p>Enrichment strategies in clinical trials involve the selective recruitment of patients who are most likely to benefit from an investigational therapy, thereby increasing the probability of detecting a true treatment effect. This approach maximizes trial efficiency by focusing resources on responsive populations while protecting patients unlikely to benefit from unnecessary exposure to experimental treatments.</p>
                    
                    <p><strong>Core Principle:</strong> Not every patient will benefit equally from an intervention. By enriching trial populations with biomarker-selected patients who have the highest likelihood of response, we can reduce sample sizes, shorten trial duration, and increase the probability of regulatory success.</p>
                </div>

                <div class="key-points">
                    <div class="key-points-title">üéØ Enrichment Strategy Goals</div>
                    <ul>
                        <li>Increase statistical power to detect treatment effects</li>
                        <li>Reduce sample size requirements and trial costs</li>
                        <li>Improve patient safety by avoiding futile treatments</li>
                        <li>Accelerate drug development timelines</li>
                        <li>Enable biomarker-driven drug approvals</li>
                    </ul>
                </div>

                <div class="visual-diagram">
                    <svg width="800" height="350" viewBox="0 0 800 350">
                        <!-- Unselected Population -->
                        <g transform="translate(120, 100)">
                            <rect x="-80" y="-60" width="160" height="120" fill="#f0f0f0" stroke="#999" stroke-width="2" rx="8"/>
                            <text x="0" y="-75" text-anchor="middle" font-size="13" font-weight="700" fill="#333">Unselected Population</text>
                            
                            <!-- Mix of responders and non-responders -->
                            <circle cx="-40" cy="-30" r="6" fill="#4CAF50" opacity="0.7"/>
                            <circle cx="-20" cy="-25" r="6" fill="#ff6b6b" opacity="0.7"/>
                            <circle cx="0" cy="-35" r="6" fill="#ff6b6b" opacity="0.7"/>
                            <circle cx="20" cy="-20" r="6" fill="#4CAF50" opacity="0.7"/>
                            <circle cx="40" cy="-30" r="6" fill="#ff6b6b" opacity="0.7"/>
                            
                            <circle cx="-40" cy="0" r="6" fill="#ff6b6b" opacity="0.7"/>
                            <circle cx="-20" cy="5" r="6" fill="#4CAF50" opacity="0.7"/>
                            <circle cx="0" cy="-5" r="6" fill="#ff6b6b" opacity="0.7"/>
                            <circle cx="20" cy="10" r="6" fill="#ff6b6b" opacity="0.7"/>
                            <circle cx="40" cy="0" r="6" fill="#4CAF50" opacity="0.7"/>
                            
                            <circle cx="-40" cy="30" r="6" fill="#ff6b6b" opacity="0.7"/>
                            <circle cx="-20" cy="35" r="6" fill="#ff6b6b" opacity="0.7"/>
                            <circle cx="0" cy="25" r="6" fill="#4CAF50" opacity="0.7"/>
                            <circle cx="20" cy="40" r="6" fill="#ff6b6b" opacity="0.7"/>
                            <circle cx="40" cy="30" r="6" fill="#4CAF50" opacity="0.7"/>
                            
                            <text x="0" y="75" text-anchor="middle" font-size="11" fill="#d63031" font-weight="600">Response Rate: 25%</text>
                            <text x="0" y="90" text-anchor="middle" font-size="11" fill="#333">n = 500 needed</text>
                        </g>

                        <!-- Biomarker Testing Arrow -->
                        <g transform="translate(250, 100)">
                            <path d="M0,0 L80,0" stroke="#1E64C8" stroke-width="3" marker-end="url(#arrow4)"/>
                            <rect x="10" y="-25" width="60" height="20" fill="white" stroke="#1E64C8" stroke-width="1" rx="4"/>
                            <text x="40" y="-10" text-anchor="middle" font-size="10" fill="#1E64C8" font-weight="700">Biomarker</text>
                            <text x="40" y="25" text-anchor="middle" font-size="10" fill="#1E64C8" font-weight="700">Screening</text>
                        </g>
                        
                        <defs>
                            <marker id="arrow4" markerWidth="10" markerHeight="10" refX="9" refY="3" orient="auto">
                                <polygon points="0 0, 10 3, 0 6" fill="#1E64C8" />
                            </marker>
                        </defs>

                        <!-- Enriched Population -->
                        <g transform="translate(450, 100)">
                            <rect x="-80" y="-60" width="160" height="120" fill="#e8f5e9" stroke="#4CAF50" stroke-width="3" rx="8"/>
                            <text x="0" y="-75" text-anchor="middle" font-size="13" font-weight="700" fill="#2e7d32">Enriched Population</text>
                            <text x="0" y="-62" text-anchor="middle" font-size="10" fill="#2e7d32">(Biomarker Positive)</text>
                            
                            <!-- Mostly responders -->
                            <circle cx="-40" cy="-30" r="6" fill="#4CAF50"/>
                            <circle cx="-20" cy="-25" r="6" fill="#4CAF50"/>
                            <circle cx="0" cy="-35" r="6" fill="#4CAF50"/>
                            <circle cx="20" cy="-20" r="6" fill="#4CAF50"/>
                            <circle cx="40" cy="-30" r="6" fill="#ff6b6b" opacity="0.5"/>
                            
                            <circle cx="-40" cy="0" r="6" fill="#4CAF50"/>
                            <circle cx="-20" cy="5" r="6" fill="#4CAF50"/>
                            <circle cx="0" cy="-5" r="6" fill="#4CAF50"/>
                            <circle cx="20" cy="10" r="6" fill="#4CAF50"/>
                            <circle cx="40" cy="0" r="6" fill="#4CAF50"/>
                            
                            <circle cx="-40" cy="30" r="6" fill="#4CAF50"/>
                            <circle cx="-20" cy="35" r="6" fill="#4CAF50"/>
                            <circle cx="0" cy="25" r="6" fill="#4CAF50"/>
                            <circle cx="20" cy="40" r="6" fill="#4CAF50"/>
                            <circle cx="40" cy="30" r="6" fill="#ff6b6b" opacity="0.5"/>
                            
                            <text x="0" y="75" text-anchor="middle" font-size="11" fill="#2e7d32" font-weight="600">Response Rate: 80%</text>
                            <text x="0" y="90" text-anchor="middle" font-size="11" fill="#333">n = 150 needed</text>
                        </g>

                        <!-- Benefits Box -->
                        <g transform="translate(650, 100)">
                            <rect x="-100" y="-60" width="130" height="120" fill="#fff3e0" stroke="#ffa500" stroke-width="2" rx="8"/>
                            <text x="-35" y="-75" text-anchor="middle" font-size="12" font-weight="700" fill="#e67e00">Benefits</text>
                            
                            <text x="-90" y="-35" font-size="10" fill="#555">‚úì 70% smaller trial</text>
                            <text x="-90" y="-20" font-size="10" fill="#555">‚úì Higher power</text>
                            <text x="-90" y="-5" font-size="10" fill="#555">‚úì Faster results</text>
                            <text x="-90" y="10" font-size="10" fill="#555">‚úì Lower cost</text>
                            <text x="-90" y="25" font-size="10" fill="#555">‚úì Clearer efficacy</text>
                            <text x="-90" y="40" font-size="10" fill="#555">‚úì Targeted label</text>
                        </g>

                        <!-- Statistical Comparison -->
                        <g transform="translate(300, 280)">
                            <rect x="-220" y="-30" width="440" height="60" fill="white" stroke="#1E64C8" stroke-width="2" rx="8"/>
                            <text x="0" y="-10" text-anchor="middle" font-size="12" font-weight="700" fill="#1E64C8">Statistical Impact</text>
                            <text x="-150" y="10" font-size="10" fill="#555">Unselected: 500 patients needed for 80% power</text>
                            <text x="-150" y="25" font-size="10" fill="#555">Enriched: 150 patients needed for 80% power</text>
                        </g>
                    </svg>
                    <div class="diagram-description">
                        Figure 4: Comparison of unselected vs biomarker-enriched clinical trial populations
                    </div>
                </div>

                <div class="method-grid">
                    <div class="method-card">
                        <div class="method-card-title">üéØ Prognostic Enrichment</div>
                        <div class="method-card-content">
                            <strong>Goal:</strong> Select patients at high risk of events
                            <br><strong>Rationale:</strong> Increases event rates, reduces follow-up time
                            <br><strong>Example:</strong> High-risk cardiovascular patients for prevention trials
                        </div>
                    </div>

                    <div class="method-card">
                        <div class="method-card-title">üß¨ Predictive Enrichment</div>
                        <div class="method-card-content">
                            <strong>Goal:</strong> Select patients likely to respond to therapy
                            <br><strong>Rationale:</strong> Increases treatment effect size
                            <br><strong>Example:</strong> HER2+ breast cancer for anti-HER2 therapy
                        </div>
                    </div>

                    <div class="method-card">
                        <div class="method-card-title">üìä Pharmacodynamic Enrichment</div>
                        <div class="method-card-content">
                            <strong>Goal:</strong> Ensure target engagement in study population
                            <br><strong>Rationale:</strong> Confirms mechanism of action
                            <br><strong>Example:</strong> Demonstrating pathway inhibition in dose-finding
                        </div>
                    </div>

                    <div class="method-card">
                        <div class="method-card-title">üî¨ Adaptive Enrichment</div>
                        <div class="method-card-content">
                            <strong>Goal:</strong> Modify enrollment during trial based on interim data
                            <br><strong>Rationale:</strong> Optimize enrollment in real-time
                            <br><strong>Example:</strong> Focus on biomarker+ subgroup if showing benefit
                        </div>
                    </div>
                </div>

                <div class="example-box">
                    <div class="example-title">
                        <span class="example-icon">üí°</span>
                        Clinical Example: Vemurafenib Development for Melanoma
                    </div>
                    <ul class="example-list">
                        <li><strong>Traditional Approach (hypothetical):</strong> All metastatic melanoma patients
                            <br>‚Üí BRAF V600E prevalence: ~50%, Response rate in unselected: 24%
                            <br>‚Üí Would require ~600 patients for adequate power</li>
                        <li><strong>Enrichment Strategy (actual):</strong> Only BRAF V600E-positive patients enrolled
                            <br>‚Üí Response rate in enriched population: 48% (doubled)
                            <br>‚Üí Required only 132 patients in Phase II trial
                            <br>‚Üí Received FDA breakthrough therapy designation</li>
                        <li><strong>Outcome:</strong> Dramatic acceleration of development timeline
                            <br>‚Üí Approval within 4 years of Phase I initiation
                            <br>‚Üí Clear indication: BRAF V600E-positive metastatic melanoma
                            <br>‚Üí Companion diagnostic (cobas¬Æ BRAF mutation test) approved simultaneously</li>
                    </ul>
                </div>

                <div class="key-points">
                    <div class="key-points-title">‚öñÔ∏è Considerations for Enrichment</div>
                    <ul>
                        <li><strong>Biomarker validation:</strong> Ensure robust analytical and clinical validity</li>
                        <li><strong>Prevalence:</strong> Balance enrichment benefit vs screening burden</li>
                        <li><strong>Label implications:</strong> Restricted indication may limit market but ensure appropriate use</li>
                        <li><strong>Health equity:</strong> Ensure biomarker testing is accessible to all populations</li>
                        <li><strong>Companion diagnostics:</strong> Develop and validate alongside therapeutic</li>
                    </ul>
                </div>
            </div>
        </div>
    </div>

</body>
</html>